Total submissions: 5
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000870464 | SCV001011962 | likely benign | Fanconi anemia | 2024-11-25 | criteria provided, single submitter | clinical testing | |
| Genetic Services Laboratory, |
RCV001816998 | SCV002068608 | likely benign | not specified | 2021-01-08 | criteria provided, single submitter | clinical testing | |
| Fulgent Genetics, |
RCV002495295 | SCV002803197 | likely benign | Fanconi anemia complementation group A | 2021-08-30 | criteria provided, single submitter | clinical testing | |
| Quest Diagnostics Nichols Institute San Juan Capistrano | RCV003478547 | SCV004221930 | uncertain significance | not provided | 2023-12-05 | criteria provided, single submitter | clinical testing | The FANCA c.1734C>T (p.Tyr578=) synonymous variant has been reported in the published literature in hereditary cancer patients (PMID: 32235514 (2020)). The frequency of this variant in the general population, 0.0002 (7/35424 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using software algorithms for the prediction of the effect of nucleotide changes on splicing yielded predictions that this variant does not affect FANCA mRNA splicing. Based on the available information, we are unable to determine the clinical significance of this variant. |
| Natera, |
RCV000870464 | SCV002095016 | likely benign | Fanconi anemia | 2020-02-28 | no assertion criteria provided | clinical testing |